Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PROF |
---|---|---|
09:32 ET | 481 | 7.63 |
10:26 ET | 400 | 7.719614 |
10:27 ET | 255 | 7.6 |
10:33 ET | 1000 | 7.7652 |
10:51 ET | 300 | 7.655 |
10:58 ET | 100 | 7.72 |
11:21 ET | 500 | 7.6746 |
11:48 ET | 1000 | 7.6796 |
11:52 ET | 100 | 7.64 |
11:54 ET | 1000 | 7.6058 |
12:01 ET | 914 | 7.64 |
12:37 ET | 1000 | 7.6058 |
01:00 ET | 100 | 7.635 |
01:06 ET | 1890 | 7.595 |
01:09 ET | 970 | 7.5 |
01:24 ET | 200 | 7.42 |
02:12 ET | 100 | 7.4101 |
02:45 ET | 1000 | 7.5 |
02:52 ET | 889 | 7.54 |
02:59 ET | 491 | 7.5407 |
03:06 ET | 2509 | 7.5 |
03:24 ET | 300 | 7.56 |
03:30 ET | 822 | 7.515 |
03:35 ET | 1278 | 7.52 |
03:37 ET | 400 | 7.52 |
03:44 ET | 1000 | 7.54 |
03:57 ET | 200 | 7.5311 |
04:00 ET | 783 | 7.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Profound Medical Corp | 260.2M | 0.0x | --- |
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $260.2M |
---|---|
Revenue (TTM) | $12.6M |
Shares Outstanding | 24.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-1.87 |
Book Value | $2.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 20.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -368.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.